Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

d by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in 10,000 male births. It is estimated that over 400,000 people worldwide suffer from hemophilia, of which only 25% currently receive therapy. It is estimated that the market for hemophilia treatment is in excess of seven billion dollars annually. There are two types of hemophilia, hemophilia A and hemophilia B. Hemophilia A is caused by a lack of Factor VIII and hemophilia B is caused by a deficiency of Factor IX.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals was founded in 2004 with the mission to revolutionize treatments for hemophilia. The Company is focused on developing products that have the potential to broaden patient access to therapy, including prophylactic use. Greater access and more frequent prophylactic therapy have been shown to reduce complications of the disease and enhance patients' long-term health and quality of life.

Underlying the Company's programs is a novel, proprietary manufacturing technology that allows a greater yield of high-quality protein. Inspiration is utilizing this technology to develop a portfolio of hemophilia and bleeding disorder products that address a $7 billion market worldwide. Inspiration's lead product candidate IB1001, an intravenous recombinant Factor IX, has completed preclinical testing and is now being evaluated in a Phase 1/2-3 clinical study in the United States and Israel and is poised to enter clinical testing in Europe.


'/>"/>
SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets  has ... - Global Strategic Business Report" report to their offering. ... Tissue Culture Supplies in US$ Thousands by the following Product Segments: ... analytics for the US, Canada , ... , and Latin America . Annual estimates ...
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... In a visit to the Menomonee Valley, Gov. Jim ... his 2007-09 state budget for the new Wisconsin Venture Center. ... sector partnership that will connect entrepreneurs with sources of capital, ... seeking deals in Wisconsin. , ,The concept was announced in ...
... - Wisconsin officials and investors who are trying to ... life science firm to relocate here have a fight on ... willing to let go of Aruna Biomedical , an ... researchers and is seeking to move from research to production. ...
... Strong, who has served as vice president of ... appointed president and chief operating officer of the Madison-based ... the company's board of directors and announced at the ... chemistry degree from the University of Wisconsin-Madison , ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Wisconsin won't get Georgia biotech without a fight 2Wisconsin won't get Georgia biotech without a fight 3
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... absorbs light and its energy is finally utilized ... Photovoltaic devices, mostly build from silicon based semiconductors, ... approach for the development of cheaper and renewable ... isolated membrane protein complexes of photosynthesis. Prof. Dr. ... from thermophilic cyanobacteria that live in a hot ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... traditional practice in animal testing has been standardization, but ... as few as two controlled environmental variables to preclinical ... number of animals needed for testing and the cost ... assistant professor of animal sciences, said the finding challenges ...
... field of golden-flowered stems swaying in an autumn breeze ... serious battles between natural enemies that took place in ... to attack by several species of insects that lay ... that can reduce or even completely prevent goldenrod from ...
... arsenal against cancer: Nanoparticles that identify, target and kill ... Led by Carl Batt, the Liberty Hyde Bailey Professor ... something like a dumbbell made of gold sandwiched ... antibodies, which target a molecule found only in colorectal ...
Cached Biology News:Intentional variation increases result validity in mouse testing 2Intentional variation increases result validity in mouse testing 3What should goldenrod do to avoid an insect attack? Duck 2What should goldenrod do to avoid an insect attack? Duck 3Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
Biology Products: